Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Reck, M. ; von Pawel, J. ; Zatloukal, P. ; Ramlau, R. ; Gorbounova, V. ; Hirsh, V. ; Leighl, N. ; Mezger, J. ; Archer, V. ; Moore, N. ; Manegold, C.

Annals of oncology, 2010-09, Vol.21 (9), p.1804-1809 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível